Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stavudine + zidovudine
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Stavudine + zidovudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy for the treatment of HIV infection. Both drugs act as thymidine analogues and inhibit HIV reverse transcriptase by causing DNA chain termination during viral replication. However, this specific combination is not recommended due to virologic antagonism between the two agents; their concurrent use can reduce antiviral efficacy and increase toxicity risk. Each drug is generally used in combination with other antiretrovirals but not together in the same regimen[2][6]. Stavudine was developed by Bristol-Myers Squibb and marketed as Zerit, while zidovudine was developed by Glaxo Wellcome (now part of GSK) and marketed as Retrovir[4][5].
- Brand names
- Zerit (stavudine)Retrovir (zidovudine)
- Other names
- 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine)ZDV (zidovudine)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on stavudine + zidovudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stavudine + zidovudine.